Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients

Area of Science:

• Pediatric Oncology
• Transplant Immunology
• Hematology

Background:

• Post-transplant lymphoproliferative disease (PTLD) is a significant complication in pediatric solid organ transplant (SOT) recipients.
• It represents a common form of lymphoproliferation in this vulnerable population.
• Over 90% of PTLD cases are B-cell in origin and Epstein Barr virus (EBV)-positive, typically emerging early post-transplant.

Purpose of the Study:

• To review the characteristics of PTLD in SOT recipients.
• To discuss current and emerging therapeutic strategies for PTLD.
• To highlight the heterogeneity and prognosis of PTLD.

Main Methods:

• Literature review of PTLD in SOT recipients.
• Analysis of pathological and clinical presentations.
• Discussion of treatment modalities including immunosuppression reduction, rituximab, and EBV-specific cytotoxic T-lymphocytes.

Main Results:

• PTLD is a heterogeneous condition with variable clinical courses.
• The majority of cases are EBV-positive B-cell lymphoproliferation.
• Prognosis is generally favorable, with a range of therapeutic responses.

Conclusions:

• PTLD management requires tailored approaches based on disease characteristics.
• Reduced immunosuppression is a primary intervention for many cases.
• Novel immune-based therapies show promise for refractory or aggressive PTLD.